entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 00:35:34 - browse：5382

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： STAT Summit: How researchers deal with rejection

focus

WSS

Is there really a nursing shortage in the U.S.?

The problems with dementia villages

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Editas, Vertex strike deal on CRISPR

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

CRISPR gene editing developments we’re watching in 2024

entertainment

entertainment

knowledge

Apple is now the first public company to be valued at $3 trillion

SNAP should offer more nutrition education

Medicare proposal to cover medical devices draws a mixed reaction

Smaller biotechs seek to piggyback on weight loss drug boom

Continuity nursing helped my family in our darkest PICU moments

Prime Medicine, Myeloid Therapeutics clash over genome

Medical leaders decry Supreme Court decision on affirmative action

Three trends to watch in biotech in 2024

The cancer drug shortage isn’t new — and neither are the solutions

STAT Summit: Ending the crisis of Black deaths in the U.S.

leisure time

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Study on Amgen’s bispecific immunotherapy produces positive data

Roche drug slashes death risk in early

STAT Summit: The economic case for universal basic health care

Smaller biotechs seek to piggyback on weight loss drug boom

knowledge

focus

focus

hotspot